Did you mean aromatase inhibitor?
Displaying drugs 901 - 925 of 2451 in total
Prasugrel
Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformation in the liver to its active metabolite, R-138727. R-138727 irreversibly binds to P2Y12 type ADP receptors on platelets thus preventing...
Approved
Matched Categories: … Platelet Aggregation Inhibitors Excl. Heparin …
Tipranavir
Tipranavir is a sulfonamide-containing dyhydropyrone and a nonpeptidic protease inhibitor that targets the HIV protease. Tipranavir and ritonavir are coadministered to treat HIV.
Approved
Investigational
Matched Categories: … Enzyme Inhibitors ... BSEP/ABCB11 Inhibitors ... OATP1B3 inhibitors ... Protease Inhibitors ... HIV Protease Inhibitors …
Ritonavir
Ritonavir is an HIV protease inhibitor that interferes with the reproductive cycle of HIV. Although it was initially developed as an independent antiviral agent, it has been shown to possess advantageous properties in combination regimens with low-dose ritonavir and other protease inhibitors. It is now more commonly used as a...
Approved
Investigational
Matched Description: … It is now more commonly used as a booster of other protease inhibitors and is available in both liquid ... possess advantageous properties in combination regimens with low-dose ritonavir and other protease inhibitors ... potent CYP3A inhibitor that increases peak and trough plasma drug concentrations of other protease inhibitors …
Matched Categories: … BCRP/ABCG2 Inhibitors ... Enzyme Inhibitors ... BSEP/ABCB11 Inhibitors ... OATP1B3 inhibitors ... Protease Inhibitors …
Matched Categories: … BCRP/ABCG2 Inhibitors ... Enzyme Inhibitors ... BSEP/ABCB11 Inhibitors ... OATP1B3 inhibitors ... Protease Inhibitors …
Ximelagatran
Ximelagatran is an anticoagulant intended to become a replacement for warfarin by overcoming the dietary restrictions, drug interaction, and monitoring issues associated with the former. In 2006, its manufacturer AstraZeneca announced that it would not attempt to market ximelagatran after reports of hepatotoxicity (liver damage) during trials, and to discontinue...
Approved
Investigational
Withdrawn
Matched Categories: … Enzyme Inhibitors ... Protease Inhibitors ... Serine Protease Inhibitors …
Amprenavir
Amprenavir is a protease inhibitor used to treat HIV infection.
Approved
Investigational
Matched Categories: … Enzyme Inhibitors ... Protease Inhibitors ... HIV Protease Inhibitors ... Viral Protease Inhibitors ... OATP1B1/SLCO1B1 Inhibitors …
Nelfinavir
Nelfinavir is a potent HIV-1 protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children. Nelfinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles.
Approved
Matched Categories: … OCT1 inhibitors ... BCRP/ABCG2 Inhibitors ... Enzyme Inhibitors ... OATP1B3 inhibitors ... Protease Inhibitors …
Belinostat
Belinostat is a novel agent that inhibits the enzyme histone deacetylase (HDAC) with a sulfonamide-hydroxamide structure. It was developed as an orphan drug to target hematological malignancies and solid tumors by TopoTarget. The safety and efficacy of belinostat is currently being evaluated for use in combination with traditional front-line therapies...
Approved
Investigational
Matched Categories: … Enzyme Inhibitors ... Histone Deacetylase Inhibitors ... Cytochrome P-450 CYP2C8 Inhibitors ... Cytochrome P-450 CYP2C9 Inhibitors ... Cytochrome P-450 Enzyme Inhibitors …
Pyridostigmine
Myasthenia gravis is an autoimmune disease involving dysfunction at the neuromuscular junction, most commonly due to autoantibodies directed against the acetylcholine receptor (AChR), which results in muscle tone loss, muscle weakness, and fatigue. Acetylcholinesterase inhibitors have been the symptomatic treatment of choice in myasthenia gravis since the 1930s with the...
Approved
Investigational
Matched Description: … [A231004] Acetylcholinesterase inhibitors have been the symptomatic treatment of choice in myasthenia …
Matched Categories: … Enzyme Inhibitors ... Cholinesterase Inhibitors …
Matched Categories: … Enzyme Inhibitors ... Cholinesterase Inhibitors …
Donepezil
In 2016, the global burden of dementia was estimated to be 43.8 million, demonstrating a significant increase from a global prevalence of 20.2 million in 1990. Donepezil, also known as Aricept, is a piperidine derivative acetylcholinesterase inhibitor used in the management of the dementia of Alzheimer's Disease, and in some...
Approved
Matched Categories: … Enzyme Inhibitors ... Cholinesterase Inhibitors …
Diclofenamide
A carbonic anhydrase inhibitor that is used in the treatment of glaucoma.
Approved
Investigational
Matched Categories: … Enzyme Inhibitors ... Carbonic Anhydrase Inhibitors …
Nefazodone
Nefazodone hydrochloride (trade name Serzone) is an antidepressant drug marketed by Bristol-Myers Squibb. Its sale was discontinued in 2003 in some countries, due to the small possibility of hepatic (liver) injury. Drug-induced hepatic injuries were associated with an risk of elevated need for a liver transplant, or even death, with...
Approved
Withdrawn
Matched Categories: … OATP1B3 inhibitors ... P-glycoprotein inhibitors ... Cytochrome P-450 CYP3A Inhibitors ... Cytochrome P-450 CYP2D6 Inhibitors ... Cytochrome P-450 CYP3A4 Inhibitors …
Etodolac
Etodolac is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic and antipyretic properties. Its therapeutic effects are due to its ability to inhibit prostaglandin synthesis. It is indicated for relief of signs and symptoms of rheumatoid arthritis and osteoarthritis.
Approved
Investigational
Vet approved
Matched Categories: … COX-2 Inhibitors ... Enzyme Inhibitors ... OAT1/SLC22A6 inhibitors ... Cyclooxygenase Inhibitors ... Selective Cyclooxygenase 2 Inhibitors (NSAIDs) …
Zolmitriptan
Zolmitriptan is a member of the triptan class of 5-hydroxytryptamine(5-HT)1B/1D/(1F) receptor agonists used to treat acute migraine.[A462, L12978] Sumatriptan was the first triptan to be developed, but had poor oral bioavailability and lipophilicity. This led to the development of second-generation triptans, including almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, and zolmitriptan. Triptans...
Approved
Investigational
Raltegravir
Raltegravir is an antiretroviral drug produced by Merck & Co., used to treat HIV infection. It received approval by the U.S. Food and Drug Administration (FDA) on 12 October 2007, the first of a new class of HIV drugs, the integrase inhibitors, to receive such approval.
Approved
Matched Description: … Drug Administration (FDA) on 12 October 2007, the first of a new class of HIV drugs, the integrase inhibitors …
Matched Categories: … Enzyme Inhibitors ... Integrase Inhibitors ... HIV Integrase Inhibitors …
Matched Categories: … Enzyme Inhibitors ... Integrase Inhibitors ... HIV Integrase Inhibitors …
Astemizole
Astemizole is a long-acting, non-sedating second generation antihistamine used in the treatment of allergy symptoms. It was withdrawn from market by the manufacturer in 1999 due to the potential to cause arrhythmias at high doses, especially when when taken with CYP inhibitors or grapefruit juice.
Approved
Withdrawn
Matched Description: … 1999 due to the potential to cause arrhythmias at high doses, especially when when taken with CYP inhibitors …
Matched Categories: … P-glycoprotein inhibitors ... Cytochrome P-450 CYP3A Inhibitors ... Cytochrome P-450 CYP3A4 Inhibitors ... Cytochrome P-450 Enzyme Inhibitors ... Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) …
Matched Categories: … P-glycoprotein inhibitors ... Cytochrome P-450 CYP3A Inhibitors ... Cytochrome P-450 CYP3A4 Inhibitors ... Cytochrome P-450 Enzyme Inhibitors ... Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) …
Ivabradine
Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure. Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus...
Approved
Rabeprazole
Rabeprazole is an antiulcer drug in the class of proton pump inhibitors. It is a prodrug - in the acid environment of the parietal cells it turns into active sulphenamide form. Rabeprazole inhibits the H+, K+ATPase of the coating gastric cells and dose-dependent oppresses basal and stimulated gastric acid secretion.
Approved
Investigational
Matched Description: … Rabeprazole is an antiulcer drug in the class of proton pump inhibitors. …
Matched Categories: … Enzyme Inhibitors ... BCRP/ABCG2 Inhibitors ... Proton Pump Inhibitors ... Proton-pump Inhibitors ... Cytochrome P-450 CYP1A2 Inhibitors …
Matched Categories: … Enzyme Inhibitors ... BCRP/ABCG2 Inhibitors ... Proton Pump Inhibitors ... Proton-pump Inhibitors ... Cytochrome P-450 CYP1A2 Inhibitors …
Metformin
Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.[L12207,A176173]
Metformin is considered an antihyperglycemic drug because it lowers blood glucose concentrations in type II diabetes without causing hypoglycemia. It is commonly described as an "insulin sensitizer", leading to a decrease in insulin...
Approved
Matched Categories: … OCT2 Inhibitors …
Selpercatinib
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including cabozantinib, ponatinib, sorafenib, sunitinib, and vandetanib, have shown efficacy in RET-driven cancers, their...
Approved
Investigational
Matched Description: … Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and ... Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors …
Matched Categories: … MATE inhibitors ... BCRP/ABCG2 Inhibitors ... MATE 1 Inhibitors ... P-glycoprotein inhibitors ... Protein Kinase Inhibitors …
Matched Categories: … MATE inhibitors ... BCRP/ABCG2 Inhibitors ... MATE 1 Inhibitors ... P-glycoprotein inhibitors ... Protein Kinase Inhibitors …
Rivaroxaban
Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15...
Approved
Matched Categories: … Enzyme Inhibitors ... Factor Xa Inhibitors ... Protease Inhibitors ... Direct factor Xa inhibitors ... Serine Protease Inhibitors …
Letermovir
Letermovir recieved approval from the FDA on November 8th, 2017 for use in prophylaxis of cytomegalovirus (CMV) infection in allogeneic hematopoietic stem cell transplant patients. It is the first of a new class of CMV anti-infectives called DNA terminase complex inhibitors. Letermovir has recieved both priority and orphan drug status...
Approved
Investigational
Matched Description: … [L1021] It is the first of a new class of CMV anti-infectives called DNA terminase complex inhibitors …
Matched Categories: … BCRP/ABCG2 Inhibitors ... BSEP/ABCB11 Inhibitors ... Enzyme Inhibitors ... OATP1B3 inhibitors ... OAT3/SLC22A8 Inhibitors …
Matched Categories: … BCRP/ABCG2 Inhibitors ... BSEP/ABCB11 Inhibitors ... Enzyme Inhibitors ... OATP1B3 inhibitors ... OAT3/SLC22A8 Inhibitors …
Abrocitinib
Abrocitinib is an oral small-molecule inhibitor of Janus kinase 1 (JAK1). Janus kinases are intracellular enzymes involved in transduction pathways that regulate hematopoiesis and immune cell function. The Janus kinase (JAK)–signal transducer and activator of transcription (STAT) signalling pathway plays a central role in the pathogenesis of a variety of...
Approved
Investigational
Matched Description: … JAK inhibitors recently attracted more attention as potential treatments for inflammatory disorders, …
Matched Categories: … OCT1 inhibitors ... Enzyme Inhibitors ... Janus Kinase Inhibitors ... P-glycoprotein inhibitors ... Protein Kinase Inhibitors …
Matched Categories: … OCT1 inhibitors ... Enzyme Inhibitors ... Janus Kinase Inhibitors ... P-glycoprotein inhibitors ... Protein Kinase Inhibitors …
Mavacamten
Mavacamten is a myosin inhibitor indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM). It received initial US FDA approval in 2022, and it is one of the first myosin inhibitors to be used in humans. Mavacamten was also approved...
Approved
Investigational
Matched Description: … It received initial US FDA approval in 2022, and it is one of the first myosin inhibitors to be used …
Irbesartan
Irbesartan is an angiotensin receptor blocker (ARB) indicated to treat hypertension or diabetic nephropathy.[L7456,L7459] It can also be used as part of a combination product with hydrochlorothiazide for patients not well controlled or not expected to be well controlled on monotherapy. Unlike angiotensin converting enzyme inhibitors, ARBs are not associated...
Approved
Investigational
Matched Description: … [L7459] Unlike angiotensin converting enzyme inhibitors, ARBs are not associated with a dry cough. …
Matched Categories: … Cytochrome P-450 CYP3A Inhibitors ... Cytochrome P-450 CYP2C8 Inhibitors ... Cytochrome P-450 CYP3A4 Inhibitors ... Cytochrome P-450 Enzyme Inhibitors ... Cytochrome P-450 CYP2C8 Inhibitors (moderate) …
Matched Categories: … Cytochrome P-450 CYP3A Inhibitors ... Cytochrome P-450 CYP2C8 Inhibitors ... Cytochrome P-450 CYP3A4 Inhibitors ... Cytochrome P-450 Enzyme Inhibitors ... Cytochrome P-450 CYP2C8 Inhibitors (moderate) …
Displaying drugs 901 - 925 of 2451 in total